77 related articles for article (PubMed ID: 23956893)
1. Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript.
Greco M; Caocci G; La Nasa G
Case Rep Hematol; 2013; 2013():871476. PubMed ID: 23956893
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib for the Frontline Treatment of Chronic Myeloid Leukemia Carrying the p230 Transcript: Dream or Reality?
Capuozzo M; Ottaiano A; Nava E; Cascone S; Cinque C; Vercellone A; Scognamiglio C; Palumbo E; Iaffaioli RV
Front Oncol; 2014; 4():17. PubMed ID: 24551597
[No Abstract] [Full Text] [Related]
3. Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course.
Verstovsek S; Lin H; Kantarjian H; Saglio G; De Micheli D; Pane F; Garcia-Manero G; Intrieri M; Rotoli B; Salvatore F; Guo JQ; Talpaz M; Specchia G; Pizzolo G; Liberati AM; Cortes J; Quackenbush RC; Arlinghaus RB
Cancer; 2002 May; 94(9):2416-25. PubMed ID: 12015767
[TBL] [Abstract][Full Text] [Related]
4. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.
Li C; Wang Y; Xu D; Zhang P; Ding X; Zhang N; Xiao M; Huang L; Meng L
Clin Lab; 2015; 61(1-2):183-6. PubMed ID: 25807654
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
[TBL] [Abstract][Full Text] [Related]
6. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
7. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
Arana-Trejo RM; Ruíz Sánchez E; Ignacio-Ibarra G; Báez de la Fuente E; Garces O; Gómez Morales E; Castro Granados M; Ovilla Martínez R; Rubio-Borja ME; Solís Anaya L; Herrera P; Delgado Llamas J; Kofman S
Clin Lab Haematol; 2002 Jun; 24(3):145-50. PubMed ID: 12067277
[TBL] [Abstract][Full Text] [Related]
8. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
9. Influence of major
Genthon A; Nicolini FE; Huguet F; Colin-Gil C; Berger M; Saugues S; Janel A; Hayette S; Cohny-Makhoul P; Cadoux N; Cayuela JM; Campos L; Guyotat D; Flandrin-Gresta P
Oncotarget; 2020 Jun; 11(26):2560-2570. PubMed ID: 32655840
[TBL] [Abstract][Full Text] [Related]
10. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
Ferri CA; Bianchini M; Bengió RM; Moiraghi EB; Gonzalez MS; Noriega MF; Larripa IB
Eur J Haematol; 2015 Mar; 94(3):270-2. PubMed ID: 24766374
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
12. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.
Haznedaroglu IC
Expert Opin Pharmacother; 2013 Oct; 14(15):2005-10. PubMed ID: 23984805
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review.
Jabbour E; Cortes J; Kantarjian H
Core Evid; 2010 Jun; 4():207-13. PubMed ID: 20694077
[TBL] [Abstract][Full Text] [Related]
14. Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.
Falchi L; Rege-Cambrin G; Fava C; Donti E; Luzi D; Giugliano E; Gubbiotti M; Schippa M; Liberati AM
Cancer Genet Cytogenet; 2010 Jun; 199(2):139-42. PubMed ID: 20471518
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Transcript-Type
Molica M; Abruzzese E; Breccia M
Mediterr J Hematol Infect Dis; 2020; 12(1):e2020062. PubMed ID: 32952973
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
17. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
19. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
Dou X; Qin Y; Huang X; Jiang Q
Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
[TBL] [Abstract][Full Text] [Related]
20. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]